SiNtx Technologies Inc (SINT)

[boston745]

Dr. Michael Chao

Michael Chao, MD has served as Director of Ansun since April 2018.  He is the Senior Managing Director of Relativity Healthcare Partners., an investment group dedicated to providing capital to companies developing promising technologies and/or offering novel services to address unmet needs. As a financier, Dr. Chao concentrates on investments that build preeminent healthcare companies. He has been involved in investments with Tanvex BioPharma, TenNor Therapeutics, EarLens, and Orphomed. He serves on the board of MidLabs and BioAnalytix, and served on the board of Owl Biomedical through its successful sale to Miltenyi Biotec. Furthermore, Dr. Chao maintains a direct link to the health community as a staff physician at the US Department of Veterans Affairs healthcare system, providing medical and surgical care for veterans and combat veterans from current and prior military conflicts.  Dr. Chao also serves on Children’s Hospital of Orange County (CHOC) Foundation Board, where he chairs the Transformational Philanthropic Venture Funding Committee, which on supports innovative ideas in pediatric health. Dr. Chao received his MD from University of California, Irvine and his BA in Biology from the University of Pennsylvania

Are they in fact related?